Doctors Hospital Health System Limited

What it is

Accredited by Joint Commission International since 2010, Doctors Hospital Health System has been the backbone of private healthcare in The Bahamas since 1955, today running a 94-bed multi-site system covering both inpatient and outpatient care. Its group includes Doctors Hospital (Bahamas) Limited, Doctors Hospital (East), (West), Bahamas Medical Center, (Harbourside), (The Institute of Learning), (Grand Bahama), and Kidney Centre Limited.

The facilities deliver primary, specialty and sub-specialty care on both an inpatient and outpatient basis, including acute care, emergency, surgery, obstetrics, laboratory services, and advanced imaging. The group pioneered the use of the 16-slice CAT scanner and MRI scanner in The Bahamas.

Who owns it

Doctors Hospital is a publicly traded company with over 1,000 Bahamian shareholders — ownership is broadly spread across the Bahamian public with no single disclosed majority shareholder. In February 2025 the board finalised the sale of 500,000 voting common shares to Health City Cayman Islands Ltd., underscoring growing regional confidence in Doctors Hospital as a premier Caribbean healthcare institution; the shares were purchased for BSD $4,990,000 (USD $4,990,000).

Health City’s parent, Narayana Health, has been actively seeking Caribbean investments; this marks its first ownership stake outside the Cayman Islands. The free float and remaining shareholder breakdown are not disclosed in available sources beyond the broad description of over 1,000 shareholders.

Who runs it

Dr. Charles Diggiss serves as President and CEO of Doctors Hospital. Dennis Deveaux is CFO of the group, and has been the public voice of its financial strategy throughout its post-COVID repositioning.

Felix Stubbs was elected Chairman following the resignation of Joseph Krukowski at the 2018 AGM.

The money, in plain words

Revenue for the full year to end-January 2025 reached over $120m — roughly double the group’s pre-COVID baseline, which the CFO had described as the target for sustainable growth. Despite hitting that top-line milestone, the health system posted a $905,603 loss for the full year to end-January 2025, weighed down by heavy investment in new facilities.

A net margin of roughly −0.8% (our calculation: −$0.9m loss on ~$120m revenue) is the arithmetic of a company choosing to spend today for returns tomorrow — not a sign of a business in distress. For the first half of fiscal 2026 (six months to end-July 2025), the group returned to profit with consolidated net income of $3.53m, up 29% year-on-year, as patient services revenue grew 5.6% over the comparable period.

The April 2024 acquisition of Kidney Centre Limited, purchased for $8.067m, contributed $6.8m in patient revenues during the final nine months of fiscal 2025 and a $574,000 profit. The company carries a BISX-listed dividend of BSD $0.060 per share — a yield of approximately 1.2% at the current price of $4.87 (our calculation) — modest but maintained through its investment phase.

What it is doing now

The $25m Grand Bahama hospital project has been confirmed as within budget following a recent deep-dive review, and the CFO has signalled it remains on track. Proceeds from the Health City share sale are earmarked to expand surgical services; both institutions hold Joint Commission International accreditation.

CEO Diggiss has indicated the capital injection will enable the group to add robotic surgery — a service that currently sends many Bahamians abroad to the United States. In March 2025, Doctors Hospital also completed a 2-for-1 stock split, halving its share price to widen access for smaller investors — the pre-split price of around BSD $10.51 became approximately BSD $5.24 on the first post-split trading day.

What to watch

• Grand Bahama hospital opening. Management remains optimistic but acknowledges headwinds ahead of this flagship opening. Timing and early revenue from the new facility will be the clearest test of whether the expansion thesis pays off.
• Return to sustained profit. The group went from a loss-making position in FY2025 to positive profitability through the first two quarters of FY2026. Sustaining that momentum — particularly once the Cath Lab upgrade, Grand Bahama hospital, and Kidney Centre integration all run in parallel — is management’s central task.
• Dividend trajectory. Management has acknowledged that dividend yields sometimes suffer during a growth phase, and has signalled a sharper focus on payouts once expansion spending eases.
• Health City partnership depth. CFO Deveaux has said the Health City relationship should lower purchasing costs for Doctors Hospital as economies of scale are leveraged. Whether those savings materialise in margins will be visible in coming annual results.

This is news, not investment advice.